---
document_datetime: 2026-01-26 16:43:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler.html
document_name: seebri-breezhaler.html
version: success
processing_time: 0.1163041
conversion_datetime: 2026-01-29 11:49:52.283271
docling_version:
  docling-serve: 1.11.0
  docling-jobkit: 1.9.0
  docling: 2.70.0
  docling-core: 2.61.0
  docling-ibm-models: 3.11.0
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Seebri Breezhaler

[RSS](/en/individual-human-medicine.xml/66298)

##### Authorised

This medicine is authorised for use in the European Union

glycopyrronium bromide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Seebri Breezhaler is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults. COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing. Seebri Breezhaler is used for maintenance (regular) treatment.

Seebri Breezhaler contains the active substance glycopyrronium bromide.

Expand section

Collapse section

## How is Seebri Breezhaler used?

Seebri Breezhaler capsules, which contain a powder for inhalation, are only used with the Seebri Breezhaler inhaler and must not be swallowed. To take a dose, the patient places a capsule into the inhaler and breathes in through the mouth the powder from the capsule.

The recommended dose is one capsule once a day at the same time each day. Patients should not use more than one capsule in a day.

Seebri Breezhaler can only be obtained with a prescription.

For more information about using Seebri Breezhaler, see the package leaflet or contact your doctor or pharmacist.

## How does Seebri Breezhaler work?

The active substance in Seebri Breezhaler, glycopyrronium bromide, is a muscarinic receptor antagonist. This means that it widens the airways by blocking muscarinic receptors (targets) in muscle cells in the lungs. Muscarinic receptors control the contraction of muscles and when glycopyrronium bromide is inhaled, it relaxes the muscles of the airways. This helps to keep the airways open and allows the patient to breathe more easily.

## What benefits of Seebri Breezhaler have been shown in studies?

Seebri Breezhaler was found to be more effective than placebo (a dummy treatment) at relieving symptoms of COPD in two main studies involving a total of 1,888 patients with COPD. In both studies, the main measure of effectiveness was improvement in patients' forced expiratory volumes (FEV1, the maximum volume of air a person can breathe out in one second).

After 12 weeks of treatment, Seebri Breezhaler increased FEV1by 97 ml more than with placebo in the first study, and by 108 ml more in the second study.

## What are the risks associated with Seebri Breezhaler?

The most common side effects with Seebri Breezhaler (seen in more than 1 patient in 100) are dry mouth, nasopharyngitis (inflammation of the nose and throat), insomnia (difficulty sleeping), muscle and bone pain and gastroenteritis (diarrhoea and vomiting). For the full list of all side effects and restrictions with Seebri Breezhaler, see the package leaflet.

## Why is Seebri Breezhaler authorised in the EU?

The European Medicines Agency noted that Seebri Breezhaler had a modest but relevant benefit for patients in terms of improving lung function, and also improved the symptoms of COPD. The Agency also noted that the fact that the medicine is used once a day may help patients to adhere to their treatment. In addition, there were no major safety concerns with Seebri Breezhaler, with side effects similar to other muscarinic receptor antagonist medicines. Therefore, the Agency decided that Seebri Breezhaler's benefits are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe use of Seebri Breezhaler?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Seebri Breezhaler have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Seebri Breezhaler are continuously monitored. Side effects reported with Seebri Breezhaler are carefully evaluated and any necessary action taken to protect patients.

A [Seebri Breezhaler : EPAR - Risk-management-plan summary](/en/documents/rmp-summary/seebri-breezhaler-epar-risk-management-plan-summary_en.pdf) is available.

## Other information about Seebri Breezhaler

Seebri Breezhaler received a marketing authorisation valid throughout the EU for Seebri Breezhaler on 28 September 2012.

For more information about treatment with Seebri Breezhaler, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Seebri Breezhaler : EPAR - Medicine overview

Reference Number: EMA/434336/2012

English (EN) (68.54 KB - PDF)

**First published:** 17/10/2012

**Last updated:** 05/07/2018

[View](/en/documents/overview/seebri-breezhaler-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-109)

български (BG) (102.14 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/bg/documents/overview/seebri-breezhaler-epar-medicine-overview_bg.pdf)

español (ES) (73.97 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/es/documents/overview/seebri-breezhaler-epar-medicine-overview_es.pdf)

čeština (CS) (97.45 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/cs/documents/overview/seebri-breezhaler-epar-medicine-overview_cs.pdf)

dansk (DA) (73.03 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/da/documents/overview/seebri-breezhaler-epar-medicine-overview_da.pdf)

Deutsch (DE) (74.56 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/de/documents/overview/seebri-breezhaler-epar-medicine-overview_de.pdf)

eesti keel (ET) (73.08 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/et/documents/overview/seebri-breezhaler-epar-medicine-overview_et.pdf)

ελληνικά (EL) (110.26 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/el/documents/overview/seebri-breezhaler-epar-medicine-overview_el.pdf)

français (FR) (75.57 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/fr/documents/overview/seebri-breezhaler-epar-medicine-overview_fr.pdf)

hrvatski (HR) (93.54 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/hr/documents/overview/seebri-breezhaler-epar-medicine-overview_hr.pdf)

italiano (IT) (73.61 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/it/documents/overview/seebri-breezhaler-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (102.78 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/lv/documents/overview/seebri-breezhaler-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (96.64 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/lt/documents/overview/seebri-breezhaler-epar-medicine-overview_lt.pdf)

magyar (HU) (95.85 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/hu/documents/overview/seebri-breezhaler-epar-medicine-overview_hu.pdf)

Malti (MT) (97.18 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/mt/documents/overview/seebri-breezhaler-epar-medicine-overview_mt.pdf)

Nederlands (NL) (73.36 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/nl/documents/overview/seebri-breezhaler-epar-medicine-overview_nl.pdf)

polski (PL) (98.35 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/pl/documents/overview/seebri-breezhaler-epar-medicine-overview_pl.pdf)

português (PT) (74.03 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/pt/documents/overview/seebri-breezhaler-epar-medicine-overview_pt.pdf)

română (RO) (102.88 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/ro/documents/overview/seebri-breezhaler-epar-medicine-overview_ro.pdf)

slovenčina (SK) (98.57 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/sk/documents/overview/seebri-breezhaler-epar-medicine-overview_sk.pdf)

slovenščina (SL) (89.38 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/sl/documents/overview/seebri-breezhaler-epar-medicine-overview_sl.pdf)

Suomi (FI) (73.5 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/fi/documents/overview/seebri-breezhaler-epar-medicine-overview_fi.pdf)

svenska (SV) (73.77 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

05/07/2018

[View](/sv/documents/overview/seebri-breezhaler-epar-medicine-overview_sv.pdf)

Seebri Breezhaler : EPAR - Risk-management-plan summary

English (EN) (138.35 KB - PDF)

**First published:** 05/07/2018

**Last updated:** 05/07/2018

[View](/en/documents/rmp-summary/seebri-breezhaler-epar-risk-management-plan-summary_en.pdf)

## Product information

Seebri Breezhaler : EPAR - Product Information

English (EN) (775.4 KB - PDF)

**First published:** 17/10/2012

**Last updated:** 26/01/2026

[View](/en/documents/product-information/seebri-breezhaler-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-902)

български (BG) (736.54 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/bg/documents/product-information/seebri-breezhaler-epar-product-information_bg.pdf)

español (ES) (694.04 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/es/documents/product-information/seebri-breezhaler-epar-product-information_es.pdf)

čeština (CS) (747.75 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/cs/documents/product-information/seebri-breezhaler-epar-product-information_cs.pdf)

dansk (DA) (688.49 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/da/documents/product-information/seebri-breezhaler-epar-product-information_da.pdf)

Deutsch (DE) (756.28 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/de/documents/product-information/seebri-breezhaler-epar-product-information_de.pdf)

eesti keel (ET) (686.73 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/et/documents/product-information/seebri-breezhaler-epar-product-information_et.pdf)

ελληνικά (EL) (735.3 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/el/documents/product-information/seebri-breezhaler-epar-product-information_el.pdf)

français (FR) (723.7 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/fr/documents/product-information/seebri-breezhaler-epar-product-information_fr.pdf)

hrvatski (HR) (739.33 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/hr/documents/product-information/seebri-breezhaler-epar-product-information_hr.pdf)

íslenska (IS) (677.85 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/is/documents/product-information/seebri-breezhaler-epar-product-information_is.pdf)

italiano (IT) (703.55 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/it/documents/product-information/seebri-breezhaler-epar-product-information_it.pdf)

latviešu valoda (LV) (708.79 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/lv/documents/product-information/seebri-breezhaler-epar-product-information_lv.pdf)

lietuvių kalba (LT) (765.02 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/lt/documents/product-information/seebri-breezhaler-epar-product-information_lt.pdf)

magyar (HU) (707.13 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/hu/documents/product-information/seebri-breezhaler-epar-product-information_hu.pdf)

Malti (MT) (747.44 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/mt/documents/product-information/seebri-breezhaler-epar-product-information_mt.pdf)

Nederlands (NL) (701.82 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/nl/documents/product-information/seebri-breezhaler-epar-product-information_nl.pdf)

norsk (NO) (683.96 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/no/documents/product-information/seebri-breezhaler-epar-product-information_no.pdf)

polski (PL) (729.74 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/pl/documents/product-information/seebri-breezhaler-epar-product-information_pl.pdf)

português (PT) (717.9 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/pt/documents/product-information/seebri-breezhaler-epar-product-information_pt.pdf)

română (RO) (754.8 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/ro/documents/product-information/seebri-breezhaler-epar-product-information_ro.pdf)

slovenčina (SK) (724.07 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/sk/documents/product-information/seebri-breezhaler-epar-product-information_sk.pdf)

slovenščina (SL) (698.88 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/sl/documents/product-information/seebri-breezhaler-epar-product-information_sl.pdf)

Suomi (FI) (683.19 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/fi/documents/product-information/seebri-breezhaler-epar-product-information_fi.pdf)

svenska (SV) (672.61 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

26/01/2026

[View](/sv/documents/product-information/seebri-breezhaler-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000320523 23/01/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Seebri Breezhaler : EPAR - All Authorised presentations

English (EN) (95.35 KB - PDF)

**First published:** 17/10/2012

**Last updated:** 04/06/2015

[View](/en/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-530)

български (BG) (104.29 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/bg/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_bg.pdf)

español (ES) (96.96 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/es/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_es.pdf)

čeština (CS) (103.3 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/cs/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (95.84 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/da/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (98.03 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/de/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (96.97 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/et/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (104.62 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/el/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_el.pdf)

français (FR) (98.11 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/fr/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (101.36 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/hr/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (98.46 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/is/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_is.pdf)

italiano (IT) (95.84 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/it/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (101.25 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/lv/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (101.05 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/lt/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (101.6 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/hu/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (101.41 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/mt/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (94.69 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/nl/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (96.89 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/no/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_no.pdf)

polski (PL) (39.55 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/pl/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_pl.pdf)

português (PT) (97.22 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/pt/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_pt.pdf)

română (RO) (143.56 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/ro/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (102.32 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/sk/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (99.22 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/sl/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (97.03 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/fi/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (96.44 KB - PDF)

**First published:**

17/10/2012

**Last updated:**

04/06/2015

[View](/sv/documents/all-authorised-presentations/seebri-breezhaler-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Seebri Breezhaler Active substance glycopyrronium bromide International non-proprietary name (INN) or common name glycopyrronium bromide Therapeutic area (MeSH) Pulmonary Disease, Chronic Obstructive Anatomical therapeutic chemical (ATC) code R03BB06

### Pharmacotherapeutic group

Drugs for obstructive airway diseases

### Therapeutic indication

Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

## Authorisation details

EMA product number EMEA/H/C/002430 Marketing authorisation holder

Novartis Europharm Limited

Vista Building

Marketing authorisation issued 28/09/2012 Revision 14

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Seebri Breezhaler : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (131.13 KB - PDF)

**First published:** 06/08/2025

**Last updated:** 26/01/2026

[View](/en/documents/procedural-steps-after/seebri-breezhaler-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Seebri Breezhaler : EPAR - Procedural steps taken and scientific information after authorisation (archive)

English (EN) (210.06 KB - PDF)

**First published:** 09/08/2013

**Last updated:** 06/08/2025

[View](/en/documents/procedural-steps-after/seebri-breezhaler-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

Seebri Breezhaler-H-C-2430-PSUV-0004 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation(s)

Reference Number: EMA/CHMP/351387/2016

English (EN) (70.56 KB - PDF)

**First published:** 25/05/2016

**Last updated:** 25/05/2016

[View](/en/documents/scientific-conclusion/seebri-breezhaler-h-c-2430-psuv-0004-epar-scientific-conclusions-and-grounds-variation-terms-marketing-authorisations_en.pdf)

## Initial marketing authorisation documents

Seebri Breezhaler : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/508029/2012

English (EN) (939.02 KB - PDF)

**First published:** 17/10/2012

**Last updated:** 17/10/2012

[View](/en/documents/assessment-report/seebri-breezhaler-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Seebri Breezhaler

Adopted

Reference Number: EMA/CHMP/422050/2012

English (EN) (53.26 KB - PDF)

**First published:** 22/06/2012

**Last updated:** 07/08/2012

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-seebri-breezhaler_en.pdf)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 26/01/2026

## Share this page

[Back to top](#main-content)